Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, Niels W C J van de Donk, Xavier Leleu, Jaime Gállego Pérez-Larraya, Salomon Manier, Ajay K Nooka, Maria Victoria Mateos, Hermann Einsele, Monique Minnema, Michele Cavo, Benjamin A Derman, Noemi Puig, Francesca Gay, P Joy Ho, Wee-Joo Chng, Efstathios Kastritis, Gösta Gahrton, Katja Weisel, Chandramouli Nagarajan, Fredik Schjesvold, Joseph Mikhael, Luciano Costa, Noopur S Raje, Elena Zamagni, Roman Hájek, Niels Weinhold, Kwee Yong, Jing Christine Ye, Surbhi Sidhana, Giampaolo Merlini, Tom Martin, Yi Lin, Ajai Chari, Rakesh Popat, Jonathan L Kaufman
Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have recently received regulatory approvals and shown unprecedented efficacy. However, these immunotherapies have unique mechanisms of action and toxicities that are different to previous treatments for myeloma, so experiences from clinical trials and early access programmes are essential for providing specific recommendations for management of patients, especially as these agents become available across many parts of the world...
May 2024: Lancet Oncology